Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CapsoVision, Inc (CV)

CapsoVision says FDA cleared AI Highlights reading tool for CapsoCam Plus

Neutral Impact 3 of 5 legal/regulatory Written later

CapsoVision said the U.S. Food and Drug Administration cleared AI Highlights, an AI-assisted reading feature for its CapsoCam Plus capsule endoscopy system, on September 25, 2026. The company announced the clearance on September 28, 2026, and the filing contains no revenue, profit, or guidance figures, so its direct financial effect on shareholders is not quantified.

Key points

  • FDA clearance received September 25, 2026; announced September 28, 2026
  • Tool flags suspected abnormal lesions in small bowel capsule studies to reduce physician review time
  • Intended for adult and pediatric patients over two years old with suspected small bowel bleeding; does not replace gastroenterologists' diagnosis

The filing

CompanyCapsoVision, Inc (CV)
Form8-K, current report
Filed with the SECSep 28, 2026, 11:03 AM ET
Accession number0001378325-26-000045

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.